RCT | Leniolisib for Activated phosphoinositide 3-kinase delta syndrome. SPECIALTIES, 22 Nov 2022 Randomized, Placebo-Controlled, Phase 3 Trial of PI3Kδ Inhibitor Leniolisib for Activated PI3Kδ Syndrome – Blood The post…